Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Chronic Lymphocytic Leukemia
NCT04008706Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Primary completion
- Nov 2025
- Countries
- 17
01
Overview
A Phase 3 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), sponsored by AstraZeneca. Started Sep 2019; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04008706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008706.